Comments
Loading...

Cognition Therapeutics Analyst Ratings

CGTXNASDAQ
Logo brought to you by Benzinga Data
$0.3140
0.013.87%
At close: -
$0.3149
0.000900.29%
After Hours: 7:47 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$14.00
Lowest Price Target1
$1.50
Consensus Price Target1
$6.25

Cognition Therapeutics Analyst Ratings and Price Targets | NASDAQ:CGTX | Benzinga

Cognition Therapeutics Inc has a consensus price target of $6.25 based on the ratings of 7 analysts. The high is $14 issued by Rodman & Renshaw on July 2, 2024. The low is $1.5 issued by B. Riley Securities on December 19, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Chardan Capital, and HC Wainwright & Co. on May 27, 2025, May 8, 2025, and March 24, 2025, respectively. With an average price target of $4 between HC Wainwright & Co., Chardan Capital, and HC Wainwright & Co., there's an implied 1170.24% upside for Cognition Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
3
Dec 24
1
Feb
2
Mar
2
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.1
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Chardan Capital
B. Riley Securities
Rodman & Renshaw
Oppenheimer

1calculated from analyst ratings

Analyst Ratings for Cognition Therapeutics

Buy NowGet Alert
05/27/2025Buy Now852.68%HC Wainwright & Co.
Raghuram Selvaraju44%
$5 → $3MaintainsBuyGet Alert
05/08/2025Buy Now1170.24%Chardan Capital
Daniil Gataulin51%
$8 → $4MaintainsBuyGet Alert
03/24/2025Buy Now1487.81%HC Wainwright & Co.
Raghuram Selvaraju44%
$6 → $5MaintainsBuyGet Alert
03/21/2025Buy Now2440.49%Chardan Capital
Daniil Gataulin51%
$11 → $8MaintainsBuyGet Alert
02/26/2025Buy Now3393.17%Chardan Capital
Daniil Gataulin51%
$11 → $11MaintainsBuyGet Alert
12/19/2024Buy Now376.34%B. Riley Securities
Mayank Mamtani71%
$1 → $1.5UpgradeNeutral → BuyGet Alert
12/19/2024Buy Now3393.17%Chardan Capital
Daniil Gataulin51%
$11 → $11MaintainsBuyGet Alert
12/19/2024Buy Now1805.37%HC Wainwright & Co.
Raghuram Selvaraju44%
$5 → $6MaintainsBuyGet Alert
11/27/2024Buy Now1487.81%HC Wainwright & Co.
Raghuram Selvaraju44%
$5 → $5ReiteratesBuy → BuyGet Alert
11/15/2024Buy Now3393.17%Chardan Capital
Daniil Gataulin51%
$11 → $11MaintainsBuyGet Alert
11/04/2024Buy Now1487.81%HC Wainwright & Co.
Raghuram Selvaraju44%
$5 → $5ReiteratesBuy → BuyGet Alert
10/31/2024Buy Now3393.17%Chardan Capital
Daniil Gataulin51%
$11 → $11MaintainsBuyGet Alert
08/12/2024Buy Now1487.81%HC Wainwright & Co.
Raghuram Selvaraju44%
$7 → $5MaintainsBuyGet Alert
08/06/2024Buy Now217.56%B. Riley Securities
Mayank Mamtani71%
$5 → $1DowngradeBuy → NeutralGet Alert
08/01/2024Buy Now2122.93%HC Wainwright & Co.
Raghuram Selvaraju44%
$10 → $7MaintainsBuyGet Alert
07/30/2024Buy NowCantor Fitzgerald
Charles Duncan69%
DowngradeOverweight → NeutralGet Alert
07/02/2024Buy Now4345.86%Rodman & Renshaw
Elemer Piros54%
$14 → $14ReiteratesBuy → BuyGet Alert
06/06/2024Buy Now3393.17%Chardan Capital
Daniil Gataulin51%
→ $11Initiates → BuyGet Alert
05/29/2024Buy Now3075.61%HC Wainwright & Co.
Raghuram Selvaraju44%
→ $10Initiates → BuyGet Alert
03/28/2024Buy Now1487.81%B. Riley Securities
Mayank Mamtani71%
→ $5ReiteratesBuy → BuyGet Alert
03/27/2024Buy Now2758.05%Oppenheimer
Jay Olson60%
$9 → $9MaintainsOutperformGet Alert
08/14/2023Buy Now1805.37%Ladenburg Thalmann
Aydin Huseynov33%
$10 → $6MaintainsBuyGet Alert
05/09/2023Buy Now2758.05%Oppenheimer
Jay Olson60%
→ $9Reiterates → OutperformGet Alert
03/24/2023Buy Now2758.05%Oppenheimer
Jay Olson60%
→ $9Reiterates → OutperformGet Alert
09/29/2022Buy Now3710.73%Cantor Fitzgerald
Charles Duncan69%
→ $12Initiates → OverweightGet Alert

FAQ

Q

What is the target price for Cognition Therapeutics (CGTX) stock?

A

The latest price target for Cognition Therapeutics (NASDAQ:CGTX) was reported by HC Wainwright & Co. on May 27, 2025. The analyst firm set a price target for $3.00 expecting CGTX to rise to within 12 months (a possible 852.68% upside). 17 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Cognition Therapeutics (CGTX)?

A

The latest analyst rating for Cognition Therapeutics (NASDAQ:CGTX) was provided by HC Wainwright & Co., and Cognition Therapeutics maintained their buy rating.

Q

When was the last upgrade for Cognition Therapeutics (CGTX)?

A

The last upgrade for Cognition Therapeutics Inc happened on December 19, 2024 when B. Riley Securities raised their price target to $1.5. B. Riley Securities previously had a neutral for Cognition Therapeutics Inc.

Q

When was the last downgrade for Cognition Therapeutics (CGTX)?

A

The last downgrade for Cognition Therapeutics Inc happened on August 6, 2024 when B. Riley Securities changed their price target from $5 to $1 for Cognition Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Cognition Therapeutics (CGTX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cognition Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cognition Therapeutics was filed on May 27, 2025 so you should expect the next rating to be made available sometime around May 27, 2026.

Q

Is the Analyst Rating Cognition Therapeutics (CGTX) correct?

A

While ratings are subjective and will change, the latest Cognition Therapeutics (CGTX) rating was a maintained with a price target of $5.00 to $3.00. The current price Cognition Therapeutics (CGTX) is trading at is $0.31, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch